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Deoxynucleoside triphosphates bearing histamine,
carboxylic acid, and hydroxyl residues – synthesis and
biochemical characterization†
Marcel Hollenstein*
Modiﬁed nucleoside triphosphates (dAHsTP, dUPOHTP, and dCValTP) bearing imidazole, hydroxyl, and carb-
oxylic acid residues connected to the purine and pyrimidine bases through alkyne linkers were prepared.
These modiﬁed dN*TPs were excellent substrates for various DNA polymerases in primer extension reac-
tions. Moreover, the combined use of terminal deoxynucleotidyl transferase (TdT) and the modiﬁed
dNTPs led to eﬃcient tailing reactions that rival those of natural counterparts. Finally, the triphosphates
were tolerated by polymerases under PCR conditions, and the ensuing modiﬁed oligonucleotides served
as templates for the regeneration of unmodiﬁed DNA. Thus, these modiﬁed dN*TPs are fully compatible
with in vitro selection methods and can be used to develop artiﬁcial peptidases based on DNA.
Introduction
The selective scission of the amide bonds of proteins and pep-
tides is of crucial importance for numerous biochemical and
biotechnological applications1 and plays a decisive role in
physiological processes.2,3 Considering the inertness of the
peptide bond (t1/2 nonenz ∼ 500 years),4,5 proficient proteolytic
enzymes with high catalytic eﬃciencies (kcat/KM) need to be
used in order to degrade proteins or peptides into smaller frag-
ments or for promoting site-specific cleavage. However, in
terms of practical applications, proteolytic enzymes are not
always applicable since they often lead to the generation of
rather short fragmentation products, lack sequence-specificity,
and cleave at multiple sites. Thus, artificial proteases based on
synthetic reagents that could favor the selective cleavage of
proteins under mild conditions are highly sought after. In this
context, transition metal complexes were suggested as prime
candidates to serve as biomimetic chemical proteases since
they are often more eﬀective than organic residues at promot-
ing the scission of inert bonds.1,6,7 Moreover, metal centers
are often combined with reagents such as β-cyclodextrins and
porphyrins that facilitate the recognition and the binding to
the target site and thus reach appreciable catalytic eﬃciencies
for the scission of amide linkages in peptides and even
proteins.8–11 However, even though some of these artificial,
transition metal-based proteases achieve cleavage with mul-
tiple turnover12 and with some site selectivity,8,13 they suﬀer
from severe drawbacks such as side-reactions, low kcat values,
and in general perform rather poorly when compared to
protein enzymes.
DNA enzymes or DNAzymes have emerged as a new and
prominent class of biomolecular catalysts, and have been
selected to accelerate an increasing number of chemical
processes.14–18 Indeed, application of SELEX and related com-
binatorial methods of in vitro selection19,20 resulted in the
identification of nucleic acid enzymes catalyzing an abun-
dance of reactions ranging from the formation of C–C,21–24
C–N,25 C–S,26 and P–O,27,28 bonds to the scission of ribo-
phosphodiester linkages.29,30 Surprisingly, the scission of amide
linkages is a reaction that has eluded catalytic nucleic acids so
far.31 Indeed, in an early eﬀort towards this goal, Joyce et al.
initially reported on the selection of a ribozyme capable of
cleaving a substrate containing an embedded 3′-NH–C(O)–
CH2-5′ linkage
32 but later realized that the reaction proceeded
through a diﬀerent mechanism leading to scission of a phos-
phodiester bond adjacent to the target site rather than the
intended amide bond.33 Similarly, Silverman et al. set out to
select a DNAzyme capable of the selective hydrolysis of amide
bonds of a tripeptide sequence,34 which culminated in the ser-
endipitous discovery of a class of very potent DNA-cleaving
DNAzymes.35,36
Recently, blending of the chemical functionalities found in
the active sites of enzymes together with tools of in vitro
selection resulted in the identification of potent DNA-
zymes.37,38 In particular, this approach allowed for the devel-
opment of highly functionalized DNA-based RNase A mimics
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that operate either in the presence of cofactors39–41 or in an
M2+-independent regime.42–47 Moreover, all the functional
groups encompassed in these modified DNAzymes seem to act
in synergy and in a cooperative manner, one of the funda-
ments in the design of de novo enzyme mimics and catalysts in
general.48 Finally, this methodology is applicable to other reac-
tions than the cleavage of ribophosphodiester bonds25,49 pro-
vided that the functional groups can easily be introduced into
DNA, i.e. that the modified nucleoside triphosphates (dN*TPs)
are compatible with methods of in vitro selection.
In this context, the enzymatic polymerization of dN*TPs
has advanced as a versatile platform for the inclusion of func-
tional groups into nucleic acids.50 Indeed, dN*TPs have been
used to introduce a myriad of functionalities including amino
acids,51–57 boronic acids,58,59 ligands for transition metals,60–65
thiols,66–68 diamondoid-like residues,69 bile acids,70 side chains
capable of organocatalysis,71 and even oligonucleotides.72
Herein, I report on the synthesis and biochemical charac-
terization of modified dN*TPs bearing the side chains found
in the active site of serine proteases.31,73,74 Indeed, dAHsTP
(7-propargylamido-histamine-dA) 1, dUPOHTP (5-pentynol-dU) 2,
and dCValTP (5-valeric acid-dC) 3 (Fig. 1) are equipped with
imidazole, hydroxyl, and carboxylic acid residues, respectively,
that are reminiscent of the side chains of the amino acids His,
Ser, and Asp that form the catalytic triad of serine proteases.
These modified dN*TPs are good substrates for a variety of
DNA polymerases in the context of primer extension reactions.
In addition, when used in conjunction with the terminal deoxy-
nucleotidyl transferase (TdT), eﬃcient tailing reactions that
rival those of the natural counterparts could be observed.
Finally, these modified dN*TPs were readily incorporated into
DNA by the polymerase chain reaction (PCR), further under-
scoring their compatibility with in vitro selection techniques.
Results and discussion
Synthesis of the modified nucleoside triphosphates
The nucleoside analogues considered herein all bear modifi-
cations either at the C5 position of the pyrimidine nucleo-
base or at the N7 of 7-deaza-2′-deoxyadenosine. Indeed, these
anchoring sites were chosen for synthetic purposes (the
modifications can easily be introduced via palladium-
catalyzed coupling reactions) and because of their minimal
disturbance and impact on substrate acceptance and duplex
stability.53,71,75–77
The adenosine analogue 1 adorned with a histamine
residue was obtained in a 6-step sequence that started with the
DMTr-protection of the known propargylamino modified
7-deaza-2′-deoxyadenosine 4 (Scheme 1).53,75,78 After removal
of the TFA masking group, nucleoside 6 was converted into
derivative 7 in 64% yield under standard 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (EDC)-mediated amide bond-for-
mation conditions using the suitably protected carboxylic acid
S2 (ESI†). The resulting intermediate 7 was then 3′-O-acetylated
under standard conditions and in good yield (84%). Following
a global acid-mediated deprotection step (quantitative yield),
nucleoside analogue 9 could be converted into the corres-
ponding triphosphate dAHsTP 1 in acceptable yields (17%) by
application of the one-pot four-step triphosphorylation
method developed by Ludwig and Eckstein.79
The synthetic path leading to dUPOHTP 2 commenced with
the Sonogashira cross-coupling reaction of the DMTr-protected
deoxyuridine analogue 11 (which was easily obtained by trityl-
ation of the commercially available 5-iodo-2′-deoxyuridine 10,
ESI†) and free 4-pentyn-1-ol as outlined in Scheme 2. After an
uneventful acetylation–detritylation sequence, precursor 14
could be converted to the corresponding triphosphate 2 by
application of the Ludwig and Eckstein conditions and was
obtained in 14% yield after a thorough RP-HPLC purification
step.79
The synthesis of the modified dC*TP analogue 3 proceeded
in an analogous manner as highlighted in Scheme 3. Indeed,
commercially available 5-iodo-2′-deoxycytidine 15 was con-
verted into the ester functionalized nucleoside 16 in good
yield (90%) using a Sonogashira cross-coupling reaction with
4-pentynoic acid methyl ester.80 The free 5′-hydroxyl residue of
Fig. 1 Chemical structures of dAHsTP 1, dUPOHTP 2, and dCValTP 3.
Scheme 1 Synthesis of modiﬁed dAHsTP 1. Reagents and conditions: (i)
DMTrCl, pyridine, rt, 15 h, 75%; (ii) NaOH, MeOH, H2O, rt, 12 h, 84%; (iii) S2,
EDC, HOBt, NMM, DMF, rt, 12 h, 64%; (iv) Ac2O, DMAP, NEt3, pyridine, 0 °C,
2.5 h, 86%; (v) DCAA, CH2Cl2, rt, 40 min, quant.; (iv) 1. 2-chloro-1,3,2-benzodioxa-
phosphorin-4-one, pyridine, dioxane, rt, 45 min; 2. (nBu3NH)2H2P2O7, DMF,
nBu3N, rt, 45 min; 3. I2, pyridine, H2O, rt, 30 min; 4. NH3(aq.), rt, 1.5 h, 17% (4
steps).
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16 was then protected with a 4,4′-dimethoxytrityl group in
moderate yields. The ensuing protected nucleoside 17 was
then acetylated yielding a mixture of the desired 3′-O-mono-
acetylated 18 (61%) and diacetylated product S4 (ESI†). Unfortu-
nately, all attempts at N-4-deacetylating S4 using ZnBr2
67 only
led to detritylation (data not shown). Finally, following
removal of the DMTr masking group under acidic conditions,
intermediate 19 could be converted to the corresponding tri-
phosphate 3 in 9% yield (4 steps), again by application of the
Ludwig–Eckstein protocol.79
Primer extension reactions
An important prerequisite for modified dN*TPs to be appli-
cable in selection experiments is that they serve as substrates
for DNA polymerases in primer extension reactions.71 Further-
more, not only do primer extension reactions constitute the
first step of an in vitro selection experiment, but they represent
the main tool for gauging the enzymatic recognition of modi-
fied dN*TPs in general. Consequently, I explored the substrate
acceptance of the modified dN*TPs 1–3 with diﬀerent DNA
polymerases under primer extension reaction conditions
(Fig. 2 and ESI†). Therefore, a variety of DNA polymerases
(Vent (exo−), Pwo, 9°Nm, and the Klenow fragment of E. coli
DNA polymerase I) were used in conjunction with the 98-mer
long template T1 and the 25-mer primer P1 (see ESI† for the
sequence compositions).70,71 The modified dN*TPs were then
investigated as to whether they could act as surrogates for their
natural counterparts, either as lone modifications (lanes 1–3,
Fig. 2), as combinations of two modified and two natural
dNTPs (lanes 4–6, Fig. 2), or in conjunction with the lone
natural dGTP (lane 7, Fig. 2). Vent (exo−) was revealed to be
highly proficient at extending primer P1 to full length since no
faster running bands were apparent in all the combinations
that were investigated. Moreover, 16 dAHs 1 and 21 dUPOH 2
that were incorporated in the nascent chain led to a significant
and expected gel retardation as compared to the natural
control sequence (compare lanes 1 and 2 with lane 8, Fig. 2).
Surprisingly, the inclusion of 18 dCVal 3 had little impact on
the gel mobility of the resulting modified DNA (lane 3 vs. lane
8, Fig. 2).
Furthermore, besides Vent (exo−), all the other DNA poly-
merases that were tested in primer extension reactions showed
very high substrate tolerance for all the dN*TPs and led to fully
extended products (Fig. S1–S3, ESI†). Interestingly, the Klenow
fragment, a prominent member of the family A polymerases,
was as eﬃcient at incorporating the modified dN*TPs as the
more tolerant family B polymerases (Fig. S2, ESI†).53,81,82
Scheme 2 Synthesis of modiﬁed dUPOHTP 2. Reagents and conditions: (i)
DMTrCl, pyridine, rt, 12 h, 93%; (ii) 4-pentyn-1-ol, Pd(PPh3)4, CuI, NEt3, DMF, rt,
12 h, 91%; (iii) Ac2O, DMAP, NEt3, pyridine, rt, 12 h, 86%; (iv) DCAA, CH2Cl2, rt,
40 min, 87%; (v) 1. 2-chloro-1,3,2-benzodioxaphosphorin-4-one, pyridine,
dioxane, rt, 45 min; 2. (nBu3NH)2H2P2O7, DMF, nBu3N, rt, 45 min; 3. I2, pyridine,
H2O, rt, 30 min; 4. NH3(aq.), rt, 1.5 h, 14% (4 steps).
Scheme 3 Synthesis of triphosphate dCValTP 3. Reagents and conditions:
(i) 4-pentynoic acid methyl ester, Pd(PPh3)4, CuI, NEt3, DMF, rt, 12 h, 90%;
(ii) DMTrCl, DMAP, NEt3, pyridine, rt, 18 h, 45%; (iii) Ac2O, DMAP, NEt3, pyridine,
0 °C, 1 h, 61%; (iv) DCAA, CH2Cl2, rt, 40 min, 92%; (v) 1. 2-chloro-1,3,2-benzodi-
oxaphosphorin-4-one, pyridine, dioxane, rt, 45 min; 2. (nBu3NH)2H2P2O7, DMF,
nBu3N, rt, 45 min; 3. I2, pyridine, H2O, rt, 30 min; 4. NaOH, H2O, 0 °C, 5 min,
9% (4 steps).
Fig. 2 Gel image (PAGE 15%) of primer extension reactions with primer P1
and template T1 using Vent (exo−) DNA polymerase. Lane 1: dAHsTP 1; lane 2:
dUPOHTP 2; lane 3: dCValTP 3; lane 4: dAHsTP 1 and dCValTP 3; lane 5: dAHsTP 1
and dUPOHTP 2; lane 6: dUPOHTP 2 and dCValTP 3; lane 7: dAHsTP 1, dUPOHTP 2,
and dCValTP 3; lane 8: natural dNTPs; lane 9: natural dNTPs without dATP; lane
10: natural dNTPs without dTTP; lane 11: natural dNTPs without dCTP; lane 12:
primer P1.
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TdT-mediated polymerization
The terminal deoxynucleotidyl transferase (TdT) is a Co2+-
dependent family X DNA polymerase that catalyzes the
random and template-independent polymerization of nucleo-
side triphosphates at the 3′-OH termini of single-stranded oligo-
nucleotides.83,84 Recently, TdT-mediated reactions using
modified dN*TPs have been employed for the generation of
3′-fluorescently labelled oligonucleotides,85,86 to confer exo-
nuclease stability to specific sequences,87 and to synthesize
ssDNAs containing stretches of nucleotides bearing redox
active tags.88 However, the tailing reaction was never used for
the incorporation of nucleotides bearing side chains that
potentially could confer catalytic activity to the ensuing modi-
fied ssDNA. Consequently, the modified dN*TPs 1–3 were
assayed for their capacity to act as substrates in TdT-mediated
tailing reactions. Thus, the 5′-32P-labelled 15 nt long primer P3
(ESI†) was incubated at 37 °C for 60 min in the presence of
TdT and varying concentrations of the modified dN*TPs
(Fig. 3).
The 7-substituted 7-deaza-deoxyadenosine derivative dAHsTP
1 was revealed to be the best substrate for TdT, since
the tailing eﬃciencies are better than those of its natural
counterpart (compare lanes 1 and 4, Fig. 3). Indeed, at a con-
centration as low as 10 μM, mainly 7–15 additional dAHs
nucleotides were incorporated along with some longer tailed
sequences, while the natural dATP led to the appendage
of a rather narrow 4–17 nucleotide distribution with little
polydisperse longer-sized oligonucleotides. Furthermore, at a
concentration of 50 μM several tens of both the dAHs and dA
nucleotides were appended. Moreover, dUPOHTP 2 (lanes 2 in
Fig. 3) led to the best tailing eﬃciencies amongst the pyrimi-
dine triphosphates, a tendency that is opposite to that
observed with natural dNTPs (vide infra). Indeed, the TdT-
mediated homopolymerization was rather ineﬀective at 10 μM
since only 2–5 additional dUPOH units were appended, but at
higher concentrations (>50 μM) only highly modified slow-
running products could be observed. Unlike its natural
counterpart, dCValTP 3 stifles the TdT and only a few
additional residues (∼3 to 15 dCValMPs) are added, even at
200 μM (lanes 3 in Fig. 3).
Polymerase chain reactions (PCR)
An additional and important part of the biochemical charac-
terization of modified dN*TPs is the assessment of their sub-
strate acceptance by DNA polymerases under PCR conditions.
Consequently, the dN*TPs 1–3 were evaluated for their capacity
to amplify the 98-mer template T170,71 flanked by a 20 nt long
forward and a 25 nt reverse primer using four diﬀerent DNA
polymerases (Fig. 4 and ESI†).
Surprisingly, unlike what had been observed for primer
extension reactions, under standard PCR conditions (2 mM
Mg2+, 200 μM dNTPs, 30 PCR cycles), only the Vent (exo−) DNA
polymerase was capable of faithfully amplifying the template,
albeit with a slightly reduced eﬃciency as compared to the
control experiment with natural dNTPs (lane 2 versus lane 8,
Fig. 4). Indeed, the 9°Nm polymerase led to a marked smearing
pattern (lane 3), the Pwo polymerase only partially accepted
the dN*TPs under these conditions and yielded a mixture of a
full length product and a shorter product (lane 4), and no
amplicon could be observed in the case of the Klenow frag-
ment (lane 5). However, when the dNTP concentration was
raised from 200 to 500 μM, an eﬃcient amplification could be
observed with Vent (exo−) (lane 6). Furthermore, additional
Mg2+ (lane 7) had no positive impact on the amplification
eﬃciency. Good amplifications were observed as well when
only one of the natural dNTPs was substituted with a modified
one (data not shown).
Fig. 3 Gel image (PAGE 15%) of the TdT-catalyzed extension reactions. Lane 1:
dAHsTP 1; lane 2: dUPOHTP 2; lane 3: dCValTP 3; lane 4: dATP; lane 5: dTTP; lane
6: dCTP; lane 7: primer P3.
Fig. 4 Agarose gel (2%) stained with ethidium bromide, showing the PCR pro-
ducts with the 98-mer template T1, a dNTP mixture composed of dAHsTP 1,
dUPOHTP 2, dCValTP 3, and natural dGTP and diﬀerent enzymes and conditions.
Lane 1: ladder; lane 2: Vent (exo−); lane 3: 9°Nm polymerase; lane 4: Pwo poly-
merase; lane 5: Klenow fragment of E. coli DNA polymerase I; lane 6: Vent
(exo−) with 500 μM dN*TPs; lane 7: Vent (exo−) with 500 μM dN*TPs and 7 mM
Mg2+; lane 8: natural dNTPs and Vent (exo−).
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In terms of in vitro selections, it is of primordial impor-
tance that single-stranded modified DNAs can be transformed
into wild-type oligonucleotides that can serve as templates for
subsequent rounds of selection.30,44 Thus, in a diﬀerent PCR
experiment a 5′-phosphorylated 79-mer long template T2
(ESI†) was amplified using the 19- and 20-mer primers P4 and
P5 in the presence of Vent (exo−) and 500 μM dNTPs. The
resulting modified dsDNA was then λ-exonuclease digested,
and used as a template for a subsequent PCR using natural
dNTPs, the same set of primers, and Vent (exo−) (Fig. S5,
ESI†).71 This experiment clearly underscores the compatibility
of the modified dN*TPs 1–3 with methods of in vitro selection
since a modified oligonucleotide could serve as a template to
regenerate natural DNA (Fig. S5, ESI†).
Finally, in order to assess the fidelity of the PCR amplifica-
tion with the modified dN*TPs 1–3, a sequencing experiment
based on the dideoxynucleoside triphosphate (ddNTP) method
developed by Sanger et al. was carried out (Fig. S6 and S7,
respectively, ESI†).52,89 Briefly, the 5′-phosphorylated template
T2 and primer P4 were used in a primer extension reaction
with Vent (exo−). The unmodified template was then λ-exo-
nuclease digested, and the resulting modified ssDNA was used
as a template for PCR with each one of the 5′-biotinylated
primers P4B and P5B. Following immobilization of the
duplexes on streptavidin coated magnetic beads, the unbioti-
nylated oligonucleotides were eluted with hydroxide washes
and then sequenced. Comparison of the sequencing patterns
of both the forward and reverse directions (Fig. S6 and S7,
ESI†) clearly reveals that no loss of sequence information
occurs upon converting a heavily modified ssDNA into its
complementary natural sequence, and that the fidelity of PCR
with the modified dN*TPs is high.
Conclusions
Three modified dN*TPs adorned with side-chains reminiscent
of the Ser, His, and Asp residues found in the active site of
serine proteases could easily be accessed in 5 or 6 steps start-
ing from known and/or commercially available precursors. The
functionalities were anchored on the C5 of pyrimidines and
the N-7 of 7-deaza-adenosine in order to minimize the destabi-
lization of duplexes and disruption of Watson–Crick base
pairing, and concomitantly, to maximize the substrate accep-
tance. All of the modified dN*TPs were found to be excellent
substrates for all four DNA polymerases, including the Klenow
fragment of DNA polymerase I, in primer extension reactions.
It is noteworthy that the polymerases readily accept and toler-
ate the presence of the negative charge of the carboxylic acid
of dCValTP 3 and allow for the incorporation of up to 3 con-
secutive dCVal residues.
Moreover, the substrate acceptance for TdT is heavily
dependent on the nature and position of the substituent and
followed the order dAHsTP > dUPOHTP > dCValTP. This trend is
opposite to what is observed for natural dNTPs, since TdT uti-
lizes dGTP and dCTP much more eﬃciently than dTTP and
more markedly, dATP.90 The additional negative charge on
dCValTP might account for its limited substrate acceptance by
TdT.
Finally, these modified dN*TPs were shown to be good sub-
strates for the Vent (exo−) DNA polymerase under PCR con-
ditions. However, unlike what was observed for primer
extension reactions, only optimized conditions and the sole
Vent (exo−) DNA polymerase led to clean and robust amplifica-
tions. The resulting modified oligonucleotides could serve as a
template to regenerate natural DNA, which is an important
prerequisite for the use of these dN*TPs in selection experi-
ments. Moreover, PCR amplification using the modified
dN*TPs and the subsequent conversion into natural DNA was
shown to proceed with high fidelity.
Thus, these three nucleoside triphosphate analogues,
equipped with functionalities that are reminiscent of the resi-
dues found in the active site of serine proteases, could be
shown to be fully compatible with methods of in vitro selec-
tion. Consequently, their simultaneous polymerization will
considerably increase the chemical landscape that can be
covered in the course of a selection experiment for the gene-
ration of DNAzymes that can promote the catalytic scission of
amide bond linkages, which is a long-standing goal in the
field of nucleic acid enzymes. Such an artificial peptidase
would be an invaluable synthetic and biochemical tool, and
selection for such an enzyme mimic is currently under way.
Experimental part
General method for the Sonogashira coupling reactions
The nucleoside was dissolved in dry DMF (5 mL mmol−1). CuI
(0.1 eq.) and NEt3 (2 eq.) were then added and the reaction
mixture was stirred for 10 min at room temperature. The
alkyne (4 eq.) and Pd(PPh3)4 (0.05 eq.) were then added in
turn. The reaction mixture was cooled down to −78 °C and
thoroughly degassed. After stirring at room temperature over-
night, the DMF was removed under reduced pressure. The
blackened crude product was then dissolved in CH2Cl2 (50 mL)
and washed with brine (50 mL). Following drying (MgSO4) and
removal of the solvent in vacuo, the residue was purified by
flash column chromatography.
General method for detritylation
The nucleoside analogue was dissolved in dry CH2Cl2 (10 mL)
and dichloroacetic acid (0.1%, 0.1 mL) was added. The orange-
coloured reaction mixture was stirred at room temperature for
40 min. MeOH (3 mL) was added and the solution was stirred
for another 5 min at room temperature. Following removal of
the solvent under reduced pressure, the residue was purified
by flash column chromatography.
Synthesis of 7-[3-(trifluoroacetamido)-propynyl]-5′-O-(4,4′-di-
methoxytrityl)-7-deaza-2′-deoxyadenosine (5). The nucleoside
analogue 4 (0.35 g, 0.9 mmol) was co-evaporated twice with dry
pyridine (5 mL). After dissolving 4 in dry pyridine (5 mL),
DMTrCl (0.36 g, 1.1 mmol) was added and the resulting
Paper Organic & Biomolecular Chemistry
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solution was stirred at rt for 15 h. After completion of the reac-
tion, 5 mL of MeOH were added and the mixture was stirred at
rt for 5 min. After removal of the solvent under reduced
pressure, the residue was purified by flash column chromato-
graphy (CH2Cl2–MeOH 95 : 5), yielding 5 as a pale yellow foam
(0.46 g, 75%). Rf: 0.46 (CH2Cl2–MeOH 9 : 1 +1% NEt3).
1H-NMR
(400 MHz, CDCl3): δ 2.41–2.52 (m, 2H), 3.37 (d, 2H, J = 4.4 Hz),
3.76 (s, 6H), 4.05 (q, 1H, J = 4.0 Hz), 4.35–4.39 (m, 2H), 4.58 (q,
1H, J = 4.9 Hz), 5.64 (br s, 2H), 6.62 (t, 1H, J = 6.2 Hz), 6.81 (dd,
4H, J = 2.0, 8.8 Hz), 7.20–7.32 (m, 7H), 7.39–7.46 (m, 3H), 8.25
(s, 1H). 13C-NMR (101 MHz, CDCl3): δ 30.9, 41.2, 53.6, 63.7,
72.1, 78.3, 83.6, 85.3, 85.7, 86.9, 94.9, 103.6, 113.6, 126.7,
127.2, 128.2, 130.3, 136.2, 136.3, 144.4, 149.8, 153.3, 157.5,
158.7. 19F-NMR (376.5 MHz, CDCl3): δ −75.67. HR MS: m/z:
calcd for C37H35O6N5F3 ([M + H]
+): 702.2534, found: 702.2524.
Synthesis of 7-[3-amino-propynyl]-5′-O-(4,4′-dimethoxytrityl)-
7-deaza-2′-deoxyadenosine (6). Nucleoside 5 (0.95 g, 1.4 mmol)
was dissolved in MeOH (8 mL). A solution of NaOH (0.16 g,
4.1 mmol) in H2O (0.78 mL) was then added and the resulting
mixture was stirred at rt for 12 h. The solvent was removed
under reduced pressure and the residue dissolved in 50 mL of
CH2Cl2. After washing with brine (1 × 50 mL) and extracting
the aqueous phase with CH2Cl2 (2 × 50 mL), the combined
organic layers were dried (MgSO4) and the solvent removed
in vacuo. Purification by flash column chromatography (CH2Cl2–
MeOH 9 : 1) yielded 6 as a white foam (0.69 g, 84%). Rf: 0.33
(CH2Cl2–MeOH 9 : 1).
1H-NMR (400 MHz, CDCl3): δ 2.29–2.51
(m, 2H), 3.30–3.40 (m, 2H), 3.64 (s, 2H), 3.77 (s, 6H), 4.03 (q,
1H, J = 3.1 Hz), 4.56 (q, 1H, J = 4.9 Hz), 5.57 (br s, 2H), 6.62 (t,
1H, J = 6.4 Hz), 6.81 (d, 4H, J = 8.7 Hz), 7.17–7.32 (m, 8H),
7.38–7.43 (m, 2H), 8.22 (s, 1H). 13C-NMR (101 MHz, CDCl3):
δ 32.6, 40.9, 55.5, 64.0, 72.6, 76.0, 83.5, 85.5, 86.8, 92.7, 96.2,
103.7, 113.5, 125.6, 127.1, 128.1, 128.4, 130.2, 130.3, 136.0,
144.8, 149.9, 153.2, 157.5, 158.8. HR MS: m/z: calcd for
C35H36O5N5 ([M + H]
+): 606.2711, found: 606.2704.
Synthesis of 7-[N-4-(methoxytrityl)-1H-imidazol-5-yl-ethyl-
amino-3-(carbamido)-propynyl]-5′-O-(4,4′-dimethoxytrityl)-7-
deaza-2′-deoxyadenosine (7). Analogue 6 (0.35 g, 0.58 mmol)
was dissolved in dry DMF (10 mL). N-Methylmorpholine
(0.13 mL, 1.2 mmol) and derivative S2 (0.34 g, 0.69 mmol)
were then added and the resulting solution was cooled down
to 0 °C. At this stage, HOBt (0.086 g, 0.64 mmol) and EDC·HCl
(0.12 g, 0.64 mmol) were added in turn. After allowing the reac-
tion mixture to warm up to room temperature, the solution
was stirred at rt for 12 h. The solvent was removed under
reduced pressure and the crude mixture was purified by flash
column chromatography by eluting with a gradual gradient of
CH2Cl2–MeOH from 95 : 5 to 9 : 1. The histamine modified
derivative 7 was obtained as a white foam (0.40 g, 64%).
Rf: 0.55 (CH2Cl2–MeOH 9 : 1).
1H-NMR (400 MHz, CDCl3):
δ 2.39–2.49 (m, 7H), 2.64 (t, 2H, J = 6.4 Hz), 3.30–3.36 (m, 2H),
3.45 (q, 2H, J = 6.2 Hz), 3.75 (s, 6H), 3.77 (s, 3H), 4.03 (q, 1H,
J = 3.7 Hz), 4.12 (d, 1H, J = 5.2 Hz), 5.55 (br s, 2H), 6.55 (d, 1H,
J = 0.8 Hz), 6.59 (t, 1H, J = 6.4 Hz), 6.77–6.83 (m, 7H), 7.00–7.02
(m, 3H), 7.07–7.13 (m, 2H), 7.18–7.32 (m, 12H), 7.35–7.40 (m,
3H), 8.18 (s, 1H). 13C-NMR (101 MHz, CDCl3): δ 27.6, 30.5,
31.9, 39.8, 40.9, 55.5, 64.0, 72.3, 83.4, 85.5, 86.8, 88.1, 95.9,
103.8, 113.5, 118.8, 125.2, 128.1, 128.2, 128.4, 129.8, 130.3,
131.3, 134.6, 136.1, 138.8, 139.2, 142.9, 144.8, 149.9, 153.3,
157.7, 158.7, 159.3, 172.1, 172.9. HR MS: m/z: calcd for
C64H63O8N8 ([M + H]
+): 1071.4763, found: 1071.4750.
Synthesis of 7-[N-4-(methoxytrityl)-1H-imidazol-5-yl-ethyl-
amino-3-(carbamido)-propynyl]-5′-O-(4,4′-dimethoxytrityl)-3′-O-
acetyl-7-deaza-2′-deoxyadenosine (8). Compound 7 (0.39 g,
0.36 mmol) was dissolved in dry pyridine (3 mL) and the
resulting solution was cooled down to 0 °C. DMAP (0.011 g,
0.09 mmol), NEt3 (0.1 mL, 0.73 mmol), and acetic anhydride
(0.09 mL, 0.91 mmol) were then added in turn. The resulting
reaction mixture was then stirred at 0 °C for 2.5 h, at which
stage MeOH (5 mL) was added and the mixture stirred for an
additional 5 min. The solvent was then removed under
reduced pressure and the residue was purified by flash column
chromatography (CH2Cl2–MeOH 96 : 4). The fully protected
analogue 8 was obtained as a white foam (0.35 g, 86%). Rf:
0.63 (CH2Cl2–MeOH 95 : 5 +1% NEt3).
1H-NMR (400 MHz,
CDCl3): δ 2.06 (s, 3H), 2.45–2.53 (m, 5H), 2.56–2.62 (m, 1H),
2.65 (t, 2H, J = 6.0 Hz), 3.35 (t, 2H, J = 3.2 Hz), 3.46 (q, 2H, J =
6.0 Hz), 3.76 (s, 6H), 3.78 (s, 3H), 4.12 (d, 2H, J = 5.6 Hz), 4.16
(q, 1H, J = 3.2 Hz), 5.37–5.40 (m, 1H), 5.87 (br s, 2H), 6.55 (d,
1H, J = 1.2 Hz), 6.62 (q, 1H, J = 4.7 Hz), 6.78–6.83 (m, 6H), 7.01
(d, 2H, J = 8.8 Hz), 7.07–7.11 (m, 4H), 7.17–7.22 (m, 2H),
7.23–7.26 (m, 3H), 7.27–7.31 (m, 10H), 7.37–7.40 (m, 2H), 8.18
(s, 1H). 13C-NMR (101 MHz, CDCl3): δ 21.3, 27.6, 30.5, 31.9,
38.4, 39.8, 55.5, 64.0, 75.3, 83.4, 83.7, 96.3, 103.8, 113.5, 118.8,
124.9, 127.14, 128.1, 128.2, 128.3, 128.5, 129.8, 130.3, 130.4,
131.3, 134.6, 135.9, 136.0, 138.9, 139.3, 142.9, 144.7, 150.2,
153.5, 157.7, 158.8, 159.3, 170.6, 172.1, 172.9. HR MS: m/z:
calcd for C66H65O9N8 ([M + H]
+): 1113.4869, found: 1113.4872.
Synthesis of 7-[1H-imidazol-5-yl-ethylamino-3-(carbamido)-
propynyl]-3′-O-acetyl-7-deaza-2′-deoxyadenosine (9). The reac-
tion was carried out with 8 (0.34 g, 0.3 mmol) by application of
the general detritylation method. The residue was purified by
flash column chromatography on silica gel by eluting with
CH2Cl2–MeOH 9 : 1 to give 9 as a white foam (0.17 g, quant.).
Rf: 0.16 (CH2Cl2–MeOH 9 : 1).
1H-NMR (400 MHz, DMSO-d6):
δ 2.09 (s, 3H), 2.30–2.38 (m, 5H), 2.45–2.50 (m, 2H), 2.60 (t,
2H, J = 7.4 Hz), 2.65–2.72 (m, 1H), 3.23 (q, 2H, J = 6.8 Hz), 3.60
(d, 2H, J = 1.6 Hz), 4.02 (q, 1H, J = 1.9 Hz), 4.09 (d, 2H, J =
5.2 Hz), 5.31 (d, 1H, J = 6.0 Hz), 6.46 (dd, 1H, J = 5.6, 9.2 Hz),
6.75 (br s, 1H), 7.50 (s, 1H), 7.69 (s, 1H), 7.88 (t, 1H, J =
3.6 Hz), 8.10 (s, 1H), 8.44 (t, 1H, J = 5.2 Hz). 13C-NMR
(101 MHz, DMSO-d6): δ 20.9, 29.2, 30.5, 30.6, 36.9, 54.9, 61.7,
74.8, 75.1, 83.3, 84.8, 89.3, 95.0, 102.3, 125.7, 134.5, 149.3,
152.7, 157.5, 170.0, 171.0, 171.6. HR MS: m/z: calcd for
C25H31O6N8 ([M + H]
+): 539.2361, found: 539.2375.
Synthesis of 5-[5-hydroxy-pentynyl]-5′-O-(4,4′-dimethoxy-
trityl)-2′-deoxyuridine (12). The reaction was carried out with
11 (0.6 g, 0.9 mmol) by application of the general method for
Sonogashira coupling reactions. However, slightly larger quan-
tities of CuI (0.4 eq.) and Pd(PPh3)4 (0.2 eq.) were used. The
crude product was purified by flash column chromatography
on silica gel (gradual gradient from CH2Cl2–MeOH 100 : 0 +1%
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NEt3 to 95 : 5) to give 12 as a white foam (0.51 g, 91%). Rf: 0.32
(CH2Cl2–MeOH 95 : 5 +1% NEt3).
1H-NMR (400 MHz, CDCl3):
δ 1.43–1.49 (m, 2H), 2.19 (t, 2H, J = 6.8 Hz), 2.23–2.28 (m, 1H),
2.48 (ddd, 1H, J = 2.8, 5.6, 13.6 Hz), 3.28 (dd, 1H, J = 3.4,
10.6 Hz), 3.40 (dd, 1H, J = 3.0, 10.6 Hz), 3.47 (t, 2H, J = 6.0 Hz),
3.77 (s, 6H), 4.06 (q, 1H, J = 2.9 Hz), 4.49–4.53 (m, 1H), 6.31
(dd, 1H, J = 5.8, 7.4 Hz), 6.82 (d, 4H, J = 9.2 Hz), 7.24–7.33
(m, 7H), 7.41 (d, 2H, J = 7.2 Hz), 8.00 (s, 1H). 13C-NMR
(101 MHz, CDCl3): δ 16.3, 30.9, 41.7, 55.5, 61.5, 63.7, 71.5,
72.5, 85.8, 86.7, 87.2, 95.0, 101.1, 113.6, 127.2, 128.2, 128.3,
130.1, 130.2, 135.8, 135.9, 141.7, 144.7, 149.4, 158.8, 162.2. HR
MS: m/z: calcd for C35H37O8N2 ([M + H]
+): 613.2544, found:
613.2537.
Synthesis of 5-[5-acetoxy-pentynyl]-5′-O-(4,4′-dimethoxy-
trityl)-3′-O-acetyl-2′-deoxyuridine (13). Compound 12 (0.3 g,
0.49 mmol) was dissolved in pyridine (3 mL) and the solution
cooled down to 0 °C. NEt3 (0.31 mL, 2.2 mmol), acetic anhy-
dride (0.12 mL, 1.2 mmol), and DMAP (0.015 g, 0.12 mmol)
were then added in turn and the reaction mixture was stirred
at rt for 5 h. MeOH (3 mL) was then added and after an
additional 5 min of stirring, the solvent was removed under
reduced pressure and the residue purified by flash column
chromatography on silica (EtOAc–hexanes 1 : 1). The fully pro-
tected compound 13 was obtained as a white foam (0.30 g,
86%). Rf: 0.34 (CH2Cl2–MeOH 95 : 5 +1% NEt3).
1H-NMR
(400 MHz, CDCl3): δ 1.34–1.41 (m, 2H), 1.91 (s. 3H), 1.99 (s,
3H), 2.06 (t, 2H, J = 7.0 Hz), 2.25–2.33 (m, 1H), 2.43–2.48 (m,
1H), 3.28–3.37 (m, 2H), 3.70 (s, 6H), 3.81 (t, 2H, J = 6.4 Hz),
4.05 (d, 1H, J = 1.6 Hz), 5.30 (d, 1H, J = 6.0 Hz), 6.25 (dd, 1H,
J = 5.6, 8.8 Hz), 6.75 (d, 4H, J = 8.8 Hz), 7.11–7.27 (m, 7H),
7.32–7.36 (m, 2H), 7.98 (s, 1H). 13C-NMR (101 MHz, CDCl3):
δ 16.5, 21.1, 21.2, 27.6, 29.9, 38.8, 55.4, 63.3, 63.8, 71.3, 75.2,
84.7, 85.3, 87.5, 94.1, 101.4, 113.6, 127.2, 128.1, 128.3, 130.2,
135.6, 135.7, 136.2, 141.7, 144.6, 149.4, 149.7, 158.9, 161.7,
170.5, 171.1. HR MS: m/z: calcd for C39H41O10N2 ([M + H]
+):
697.2756, found: 697.2763.
Synthesis of 5-[5-acetoxy-pentynyl]-3′-O-acetyl-2′-deoxy-
uridine (14). The reaction was carried out with 13 (0.43 g,
0.6 mmol) by application of the general detritylation method.
The residue was purified by flash column chromatography on
silica gel by eluting with CH2Cl2–MeOH 9 : 1 to give 9 as a pale
yellow solid (0.21 g, 87%). Rf: 0.16 (CH2Cl2–MeOH 9 : 1).
1H-NMR (400 MHz, DMSO-d6): δ 1.76–1.83 (m, 2H), 2.01 (s,
3H), 2.06 (s, 3H), 2.25–2.32 (m, 2H), 2.45 (t, 2H, J = 7.2 Hz),
3.63 (d, 2H, J = 2.8 Hz), 4.01 (q, 1H, J = 2.8 Hz), 4.09 (t, 2H, J =
6.4 Hz), 5.20–5.22 (m, 1H), 6.14 (apparent t, 1H, J = 7.2 Hz),
8.13 (s, 1H), 11.72 (s, 1H). 13C-NMR (101 MHz, DMSO-d6):
δ 15.6, 20.7, 20.8, 27.3, 37.1, 61.1, 62.7, 63.4, 73.1, 74.6, 84.4,
84.9, 92.3, 99.2, 142.6, 149.5, 161.6, 165.5, 170.0, 170.4. HR
MS: m/z: calcd for C18H23O8N2 ([M + H]
+): 395.1449, found:
395.1441.
Synthesis of 5-[5-(pent-1-ynylic acid methyl ester)]-2′-deoxy-
cytidine (16). Nucleoside analogue 16 (pale yellow solid,
0.52 g, 90%) was obtained by application of the general
method for Sonogashira coupling reactions starting from 15
(0.6 g, 1.7 mmol) and after purification by flash column
chromatography on silica gel (gradient from CH2Cl2–MeOH
96 : 4 to 9 : 1). Rf: 0.20 (CH2Cl2–MeOH 9 : 1).
1H-NMR
(400 MHz, DMSO-d6): δ 1.93–2.00 (m, 1H), 2.10–2.16 (m, 1H),
2.60–2.67 (m, 4H), 3.52–3.61 (m, 2H), 3.62 (s, 3H), 3.78 (q, 1H.
J = 3.3 Hz), 4.17–4.22 (m, 1H), 5.04 (t, 1H, J = 5.2 Hz), 5.18 (d,
1H, J = 4.0 Hz), 6.10 (t, 1H, J = 6.6 Hz), 6.68 (br s, 1H), 7.71 (br
s, 1H), 8.06 (s, 1H). 13C-NMR (101 MHz, DMSO-d6): δ 15.0,
32.4, 45.7, 51.9, 61.0, 70.2, 72.5, 85.3, 87.4, 90.0, 94.3, 143.5,
153.5, 164.4, 172.2. HR MS: m/z: calcd for C15H20O6N3
([M + H]+): 338.1347, found: 338.1344.
Synthesis of 5-[5-(pent-1-ynylic acid methyl ester)]-5′-O-(4,4′-
dimethoxytrityl)-2′-deoxycytidine (17). Derivative 16 (0.27 g,
0.81 mmol) was dissolved in pyridine (4 mL). DMTrCl (0.33 g,
1 mmol), NEt3 (0.22 mL, 1.6 mmol), and DMAP (0.024 g,
0.2 mmol) were then added to the solution and stirred for 18 h
at rt. MeOH (2 mL) was added and the yellow solution was
stirred for an additional 5 min. After removal of the solvent
under reduced pressure, the residue was dissolved in CH2Cl2
(50 mL) and washed with NaHCO3 (satd., 1 × 50 mL). The
aqueous phase was extracted with CH2Cl2 (2 × 50 mL) and the
combined organic layers were dried (MgSO4). After removal of
the solvent in vacuo, the residue was purified by flash column
chromatography on silica gel by eluting with CH2Cl2–MeOH
96 : 4 to give 17 as a pale yellow solid (0.23 g, 45%). Rf: 0.45
(CH2Cl2–MeOH 9 : 1 +1% NEt3).
1H-NMR (400 MHz, CDCl3):
δ 2.08–2.15 (m, 1H), 2.25–2.31 (m, 2H), 2.33–2.39 (m, 2H),
2.63–2.68 (m, 1H), 3.20–3.28 (m, 2H), 3.58 (s, 3H), 3.69 (s, 6H),
4.06 (q, 1H, J = 3.3 Hz), 4.40–4.43 (m, 1H), 5.89 (br s, 1H), 6.24
(t, 1H, J = 6.4 Hz), 6.42 (br s, 1H), 6.73 (dd, 4H, J = 1.2, 8.8 Hz),
7.09–7.20 (m, 3H), 7.23–7.27 (m, 4H), 7.35 (d, 2H, J = 7.2 Hz),
8.01 (s, 1H). 13C-NMR (101 MHz, CDCl3): δ 15.5, 33.0, 46.2,
52.1, 55.4, 63.8, 72.3, 72.5, 86.6, 87.0, 87.1, 91.4, 94.5, 113.5,
127.1, 128.1, 128.2, 130.1, 130.2, 135.9, 136.0, 143.4, 144.8,
154.9, 158.8, 165.2, 172.7. HR MS: m/z: calcd for C36H38O8N3
([M + H]+): 640.2653, found: 640.2647.
Synthesis of 5-[5-(pent-1-ynylic acid methyl ester)]-5′-O-(4,4′-
dimethoxytrityl)-3′-O-acetyl-2′-deoxycytidine (18). The DMTr-
protected nucleoside 17 (0.35 g, 0.55 mmol) was dissolved in
dry pyridine (3 mL) and the solution was cooled down to 0 °C.
DMAP (0.017 g, 0.14 mmol) and NEt3 (0.15 mL, 1.1 mmol)
were then added. Acetic anhydride (0.13 mL, 1.4 mmol) was
then added dropwise to the solution. The reaction was stirred
at 0 °C. TLC analysis (CH2Cl2–MeOH 95 : 5 +1% NEt3, Rf (start-
ing material): 0.38; Rf (18): 0.5; Rf (S2): 0.86) revealed the com-
plete disappearance of the starting material. MeOH (3 mL) was
then added and the solution was stirred for an additional
5 min at 0 °C. The solvents were removed under reduced
pressure and the crude product was purified by flash column
chromatography on silica gel (gradient from CH2Cl2–MeOH
98 : 2 to 95 : 5), yielding 18 (0.23 g, 61%) and S4 (0.12 g, 30%)
both as white foams. Characterization for 18: 1H-NMR
(400 MHz, CDCl3): δ 2.04 (s, 3H), 2.20–2.28 (m, 1H), 2.35–2.40
(m, 2H), 2.43–2.48 (m, 2H), 2.69 (ddd, 1H, J = 1.5, 5.5, 14.1
Hz), 3.06–3.12 (m, 1H), 3.31–3.39 (m, 2H), 3.66 (s, 3H), 3.77 (s,
6H), 4.16 (q, 1H, J = 2.5 Hz), 5.34 (apparent d, 1H, J = 6.0 Hz),
6.10 (br s, 1H), 6.20 (br s, 1H), 6.31 (dd, 1H, J = 5.4, 8.2 Hz),
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6.81 (dd, 4H, J = 1.8, 9.0 Hz), 7.16–7.33 (m, 8H), 7.40 (apparent
d, 1H, J = 7.2 Hz), 8.07 (s, 1H). 13C-NMR (101 MHz, CDCl3):
δ 15.6, 21.2, 33.0, 39.7, 52.2, 55.5, 63.8, 72.2, 75.4, 84.6, 86.8,
87.3, 91.6, 94.8, 113.5, 127.4, 128.1, 128.2, 130.1, 130.2, 135.7,
135.8, 143.2, 144.7, 154.3, 158.9, 164.9, 170.6, 172.7. HR MS:
m/z: calcd for C38H40O9N3 ([M + H]
+): 682.2759, found:
682.2750.
Synthesis of 5-[5-(pent-1-ynylic acid methyl ester)]-3′-O-
acetyl-2′-deoxycytidine (19). The reaction was carried out with
18 (0.22 g, 0.3 mmol) by application of the general detritylation
method. The residue was purified by flash column chromato-
graphy on silica gel (gradient from CH2Cl2–MeOH 100 : 0 to
94 : 6), to give 9 as a white solid (0.11 g, 92%). Rf: 0.31
(CH2Cl2–MeOH 95 : 5 +% NEt3).
1H-NMR (400 MHz, DMSO-d6):
δ 2.06 (s, 3H), 2.11–2.19 (m, 1H), 2.25–2.32 (m, 1H), 2.63–2.67
(m, 4H), 3.56–3.60 (m, 1H), 3.64 (s, 3H), 4.01 (q, 1H, J =
2.8 Hz), 5.19 (apparent d, 2H, J = 6.0 Hz), 6.15 (dd, 1H, J = 5.8,
7.8 Hz), 6.83 (br s, 1H), 7.73 (br s, 1H), 8.06 (s, 1H). 13C-NMR
(101 MHz, DMSO-d6): δ 15.0, 20.8, 32.4, 37.8, 51.5, 61.2, 72.3,
74.7, 84.9, 85.2, 90.5, 94.5, 143.3, 153.5, 164.4, 170.0, 172.2.
HR MS: m/z: calcd for C17H22O7N3 ([M + H]
+): 380.1452, found:
380.1443.
Triphosphorylation of nucleosides
General method for the triphosphorylation of nucleosides.
The nucleoside was co-evaporated twice with dry pyridine
(1 mL) and then dried under vacuum overnight. After dissol-
ving the nucleoside in dry pyridine (0.2 mL), dry dioxane
(0.4 mL) was added, followed by the addition of 2-chloro-1,3,2-
benzodioxaphosphorin-4-one (1.1 eq.). The reaction mixture
was stirred at room temperature for 45 min. A solution of tri-
butylammonium pyrophosphate (1.3 eq.) in dry DMF (170 μL)
and tributylamine (58 μL) was then added and the resulting
solution was stirred at room temperature for 45 min. Iodine
(1.6 eq.) in a mixture of pyridine (980 μL) and water (20 μL)
was then added and the resulting dark solution was stirred at
room temperature for 30 min. Excess iodine was then
quenched by addition of a solution of sodium thiosulfate
(10%) and the solvents were removed under reduced pressure
(water bath ≤30 °C). Water (5 mL) was then added and the
mixture was allowed to stand at room temperature for 30 min.
Following removal of the various protecting groups (see below)
and evaporation of the solvent, the crude triphosphates were
precipitated with NaClO4 in acetone (2%) and then purified by
RP-HPLC. The appropriate fractions were freeze-dried and co-
evaporated several times with water.
HPLC of triphosphates
The purification of the various triphosphates was carried out
on a Phenomenex Jupiter semi-preparative RP-HPLC column
(see ESI†) at a flow rate of 3.5 mL min−1, using a triethylammo-
nium bicarbonate (TEAB) buﬀer system (eluent I: 50 mM
TEAB, pH 7.7; eluent II: 50 mM TEAB in CH3CN–H2O 1 : 1),
and one of the programs highlighted in Table 1.
Modified dATP 1 (dAHsTP). This modified triphosphate was
obtained by application of the general triphosphorylation
procedure starting from 9 (35 mg, 0.065 mmol). Deprotection
was carried out by incubation in aqueous NH3 (10 mL) at rt for
1.5 h. RP-HPLC purification (program A, Rt = 26.9 min) yielded
1 as its triethylammonium salt (pale yellow solid, 12 mg,
17%). 1H-NMR (400 MHz, D2O): δ 1.31 (t, 27 H, J = 7.2 Hz),
2.43–2.52 (m, 1H), 2.56–2.67 (m, 5H), 2.72 (t, 2H, J = 7.0 Hz),
3.00–3.05 (m, 1H), 3.06–3.13 (m, 2H), 3.22 (q, 18H, J = 7.3 Hz),
3.29–3.56 (m, 2H), 3.52 (q, 1H, J = 7.2 Hz), 4.21 (d, 2H, J = 4.0
Hz), 4.26–4.32 (m, 2H), 6.52 (t, 1H, J = 6.8 Hz), 7.02 (s, 1H),
7.74 (s, 1H), 8.50 (s, 1H). 13P-NMR (121.4 MHz, D2O): δ −5.18
(d, 1P, J = 18.5 Hz, Pγ), −5.56 (d, 1P, J = 19.4 Hz, Pα), −20.32
(t, 1P, J = 17.3 Hz, Pβ). MS (MALDI
−): m/z calcd for
C23H30N8O14P3
−: 735.11 [M − H]−; found: 734.84; UV: λmax =
282, 240 nm.
Modified dUTP 2 (dUPOHTP). Triphosphate 2 was syn-
thesized by application of the general triphosphorylation pro-
cedure starting from 14 (40 mg, 0.101 mmol). Deprotection
was carried out by incubation in aqueous NH3 (10 mL) at rt for
1.5 h. RP-HPLC purification (program A, Rt = 24.7 min) yielded
1 as its triethylammonium salt (white solid, 12 mg, 14%).
1H-NMR (300 MHz, D2O): δ 1.28 (t, 27H, J = 7.5 Hz), 1.82
(t, 2H, J = 6.6 Hz), 2.34–2.41 (m, 2H), 2.51 (t, 2H, J = 7.1 Hz),
2.96–3.11 (m, 2H), 3.20 (q, 18H, J = 7.3 Hz), 3.73 (t, 2H, J =
6.3 Hz), 4.14 (m, 3H), 4.59–4.68 (m,1H), 6.29 (t, 1H, J = 6.6 Hz),
8.05 (s, 1H). 13P-NMR (121.4 MHz, D2O): δ −10.27 (d, 1P, J =
23.2 Hz, Pγ), −11.34 (d, 1P, J = 20.5 Hz, Pα), −23.11 (t, 1P, J =
18.0 Hz, Pβ). MS (MALDI
−): m/z calcd for C14H20N2O15P3
−:
549.01 [M − H]−; found: 548.76; UV: λmax = 233, 292 nm.
Modified dCTP 3 (dCValTP). Analogue 3 was obtained by
application of the general triphosphorylation procedure start-
ing from 19 (45 mg, 0.119 mmol). Deprotection: the crude
reaction mixture was dissolved in H2O (1.69 mL). After cooling
to 0 °C, NaOH (380 μL, 2.5 M; 0.46 M final concentration) was
added and the reaction stirred at 0 °C for 5 min. The mixture
was then neutralized by adding NaH2PO4 buﬀer (925 μL; 1 M,
pH 1.9) and further diluted by addition of H2O (3 mL). The
solvent was then removed in vacuo and the residue purified
by RP-HPLC using program B (Rt = 21.8 min). dC
ValTP 3 was
obtained as its triethylammonium salt (white solid, 10 mg,
9%). 1H-NMR (300 MHz, D2O): δ 1.28 (t, 27H, J = 7.4 Hz),
2.25–2.35 (m, 1H), 2.38–2.45 (m, 1H), 2.49 (t, 2H, J = 6.9 Hz),
2.68 (t, 2H, J = 6.9 Hz), 2.95–3.01 (m, 1H), 3.03–3.11 (m, 2H),
3.20 (q, 18H, J = 7.3 Hz), 3.39 (q, 2H, J = 7.3 Hz), 4.20 (d,
2H, J = 4.5 Hz), 4.59 (t, 1H, J = 2.7 Hz), 6.27 (t, 1H, J = 6.8 Hz),
8.03 (s, 1H). 13P-NMR (121.4 MHz, D2O): δ −10.71 (d, 1P,
Table 1 HPLC programs used for the puriﬁcation of the dNTPs
Time (min) Program A (% II) Program B (% II) Time (min)
0 0 0 0
8 0 0 8
50 50 17 31
52 100 80 33
54 100 80 35
56 0 0 37
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J = 14.6 Hz, Pγ), −11.27 (d, 1P, J = 19.3 Hz, Pα), −23.18 (d,
1P, J = 20.6 Hz, Pβ). MS (MALDI
−): m/z calcd for
C14H19N3O15P3
−: 562.00 [M − H]−; found: 562.16; UV: λmax =
209, 235, 293 nm.
Primer extension experiments. The 5′-32P-labelled primer P1
(ca. 1 pmol) and 10 pmol of primer P1 were annealed to appro-
priate template T1 (10 pmol) in the presence of 10× enzyme
buﬀer (provided by the supplier of the DNA polymerase) by
heating to 95 °C and then gradually cooling to room temp-
erature (over 30 min). The appropriate DNA polymerase (1 U) was
then added to the annealed oligonucleotides mixture at 4 °C.
Finally, dNTPs (final concentration of 100 μM) were added
for a total reaction volume of 20 μL. Following incubation
at the optimal temperature for the enzyme, the reactions
were quenched by adding stop solution (20 μL; formamide
(70%), ethylenediaminetetraacetic acid (EDTA; 50 mM),
bromophenol (0.1%), xylene cyanol (0.1%)). The reaction
mixtures were subjected to gel electrophoresis in denaturing
polyacrylamide gel (15%) containing trisborate-EDTA (TBE)
1× buﬀer (pH 8) and urea (7 M). Visualization was performed
by phosphorimaging.
Standard conditions for TdT-mediated insertion of modified
triphosphates into a DNA primer. A solution containing
7 pmol of primer P3 (ESI†), ∼2 pmol of 5′-32P-radio-labelled
P3, and 4 U of TdT was added to a mixture composed of
the appropriate concentration of dNTPs (10, 50, 100 or 200 μM
final), reaction buﬀer, and H2O (for a total reaction volume
of 10 μL). The reaction mixtures were then incubated at 37 °C
for 60 min and quenched by addition of 10 μL of loading
buﬀer. The reaction products were then resolved by electro-
phoresis (PAGE 15%) and visualized by phosphorimager
analysis.
Polymerase chain reactions. The PCR reaction mixtures
(20 μL total) contained both primers (400 nM each; P1 and P2,
see the ESI† for the sequences), template T1 (25 nM), dNTPs
(200 μM; both natural and modified), and Vent (exo−) (1 U) in
the reaction buﬀer (Thermopol buﬀer) provided by the manu-
facturer. The PCRs were carried out in a Gene Q Thermal
Cycler from Bioconcept and 30 cycles were performed. Each
cycle included denaturation at 94 °C for 1 min, annealing for
1 min at 55 °C, and extension for 1.5 min at 72 °C. A final
extension step of 5 min at 72 °C was included. After the com-
pletion of the reactions, 20 μL of 2× sucrose loading buﬀer was
added. All PCR products were analysed by agarose gels (2%) in
1× TBE buﬀer, containing ethidium bromide. The gels were
visualized by phosphorimager analysis.
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